Showing results (191-200 of 224) with videos related to
Sort By:
Pageof 23
Oncology and Therapy|May 14, 2025
Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid TumorsDaphne W M Voogd, Merel J J Lucassen, Ruud van der Noll, et al.Pharmaceutical Research|October 11, 2023
Cortisol as Biomarker for CYP17-Inhibition is Associated with Therapy Outcome of Abiraterone AcetateMaaike A C Bruin, Ma Ida Mohmaed Ali, Merel van Nuland, et al.British Journal of Clinical Pharmacology|July 27, 2018
Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteersLinda M Henricks, Bart A W Jacobs, Didier Meulendijks, et al.Cancer Research|November 19, 2009
Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicityRobert A B van Waterschoot, Jurjen S Lagas, Els Wagenaar, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2002
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignanciesMiguel A Villalona-Calero, S Gail Eckhardt, Geoffrey Weiss, et al.Cancer Chemotherapy and Pharmacology|October 12, 2012
Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023Bojana Milojkovic Kerklaan, Bojana Milojkovic Kerklaan, Veronique Diéras, et al.Acta Pharmaceutica Sinica. B|March 6, 2023
Carboxylesterase 1 family knockout alters drug disposition and lipid metabolismChangpei Gan, Jing Wang, Alejandra Martínez-Chávez, et al.Haematologica|December 15, 2015
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)Christoph Driessen, Marianne Kraus, Markus Joerger, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 4, 2022
A simple extemporaneous oral suspension of aprepitant yields sufficient pharmacokinetic exposure in childrenA Laura Nijstad, Evelien de Vos-Kerkhof, Catherine F Enters-Weijnen, et al.Journal of Clinical Pharmacology|October 4, 2023
Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with MidazolamLisa T van der Heijden, Claire A Ribbers, Marit A C Vermunt, et al.Pageof 23